GAMCO Investors’s Ligand Pharmaceuticals LGND Stock Holding History

GAMCO Investors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-13,626	Closed	-$618K	–	874
2020 Q1	$618K	Hold	13,626	–	–	0.01%	628
2019 Q4	$886K	Hold	13,626	–	–	0.01%	638
2019 Q3	$846K	Hold	13,626	–	–	0.01%	633
2019 Q2	$970K	Hold	13,626	–	–	0.01%	612
2019 Q1	$1.07M	Buy	13,626 +4,008	+42%	+$304K	0.01%	567
2018 Q4	$814K	Buy	9,618 +4,809	+100%	+$513K	0.01%	572
2018 Q3	$823K	Hold	4,809	–	–	0.01%	604
2018 Q2	$622K	Sell	4,809 -4,809	-50%	-$537K	﹤0.01%	653
2018 Q1	$991K	Hold	9,618	–	–	0.01%	559
2017 Q4	$822K	Buy	9,618 +1,603	+20%	+$139K	0.01%	604
2017 Q3	$681K	Hold	8,015	–	–	﹤0.01%	634
2017 Q2	$607K	Hold	8,015	–	–	﹤0.01%	660
2017 Q1	$529K	Buy	+8,015	New	+$527K	﹤0.01%	674

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

SDJVC

St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

GAMCO Investors's LGND Position: Q2 2020 in Review

GAMCO Investors sold out of Ligand Pharmaceuticals (LGND) in Q2 2020, closing a stake of 13,626 shares — an estimated $618K sold.

GAMCO Investors first reported a position in LGND in Q1 2017 and held it in 13 quarters. The position peaked at $1.07M in Q1 2019. 262 funds tracked by Wall St. Rank hold LGND as of Q2 2020.

GAMCO Investors reported no remaining Ligand Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
GAMCO Investors sold 13,626 Ligand Pharmaceuticals shares in Q2 2020, an estimated $618K.
GAMCO Investors first reported a position in Ligand Pharmaceuticals in Q1 2017 and held it in 13 quarters.
GAMCO Investors's Ligand Pharmaceuticals position peaked at $1.07M in Q1 2019.
262 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2020.

Based on GAMCO Investors's 13F filing for Q2 2020, filed 13 Aug 2020.